Previous 10 | Next 10 |
2024-02-25 05:00:00 ET Summary AlphaGen Therapeutics and ArtBio, two targeted RLT companies, forged a far-reaching agreement to expand ArtBio’s market and develop new RLTs. Biocytogen Pharma signed an antibody evaluation/option agreement with Gilead Sciences, granting acces...
2024-02-23 13:22:45 ET Legend Biotech ( NASDAQ: LEGN ) shares gained over 6% on Friday after an expert panel of the EU drug regulator, the European Medicines Agency (EMA), adopted a positive opinion for the label expansion of Carvykti (ciltacabtagene autoleucel) to include adult...
2024-02-23 09:58:33 ET Johnson & Johnson's ( NYSE: JNJ ) Janssen Pharmaceutical unit announced Friday that an expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed its CAR-T cell therapy Carvykti to expand its label for multiple myeloma.... R...
CARVYKTI ® is the first CAR-T therapy for patients with relapsed and refractory multiple myeloma to receive a positive CHMP opinion for second line treatment Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today the Commi...
2024-02-18 03:05:00 ET Summary Baron is an asset management firm focused on delivering growth equity investment solutions known for a long-term, fundamental, active approach to growth investing. During Q4 2023, Baron Opportunity Fund rose 15.10% (inst.) and for the full-year 2023,...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, will host a conference call for investors at 8:00 am ET on Monday, March 11, 2024, to review fourth-quarter...
2024-02-07 11:28:54 ET More on I-Mab Biopharma Seeking Alpha’s Quant Rating on I-Mab Biopharma Historical earnings data for I-Mab Biopharma Financial information for I-Mab Biopharma Read the full article on Seeking Alpha For further details see...
2024-01-29 13:47:30 ET Summary Today, we take a look at Legend Biotech Corporation, a commercial-stage biopharmaceutical company focused on developing cell therapies for oncology and other indications. The company has one approved product on the market, LCAR-B38M, for the treatmen...
2024-01-23 09:47:13 ET Bank of Montreal (FNGD) FNGD is trading DOWN for the last 4 days, and it at trading at $5.17 with volume of 1,660,669 and a one day change of $-0.07 (-1.34%). Bank of Montreal has a 52-week low of 5.10 and a 52-week high of $42.58. The business's 50-day moving...
2024-01-23 07:08:06 ET More on Genmab, Johnson & Johnson, etc. Johnson & Johnson: Is The Dividend Still Safe After The Kenvue Split-Off? Johnson & Johnson Remains A Safe Bet Amidst Talc Lawsuits And Ambrx Acquisition Genmab: 3 Trends To Track For A Strong...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...
VANCOUVER – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number of cancer cases in younger age groups than before. While researchers continue to search for a reason why this is happening, s...
2024-06-17 07:00:07 ET Asthika Goonewardene from Truist Financial issued a price target of $88.00 for LEGN on 2024-06-17 06:19:00. The adjusted price target was set to $88.00. At the time of the announcement, LEGN was trading at $42.45. The overall price target consensus...